| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperkalemia | 14 | 2023 | 70 | 6.400 |
Why?
|
| Emergency Service, Hospital | 18 | 2025 | 1161 | 2.070 |
Why?
|
| Emergency Medical Services | 7 | 2024 | 414 | 1.300 |
Why?
|
| Acute Coronary Syndrome | 5 | 2025 | 244 | 1.260 |
Why?
|
| Heart Failure | 9 | 2025 | 2386 | 1.250 |
Why?
|
| Polymers | 3 | 2019 | 110 | 1.250 |
Why?
|
| Potassium | 7 | 2022 | 271 | 1.190 |
Why?
|
| Heart Arrest | 7 | 2025 | 373 | 1.170 |
Why?
|
| Pain | 3 | 2022 | 461 | 0.810 |
Why?
|
| Silicates | 3 | 2020 | 10 | 0.780 |
Why?
|
| Personal Protective Equipment | 2 | 2022 | 52 | 0.740 |
Why?
|
| Airway Management | 2 | 2022 | 65 | 0.740 |
Why?
|
| Cardiopulmonary Resuscitation | 6 | 2025 | 333 | 0.730 |
Why?
|
| Atrial Flutter | 1 | 2021 | 34 | 0.720 |
Why?
|
| Heart Injuries | 1 | 2021 | 47 | 0.720 |
Why?
|
| Pulmonary Edema | 1 | 2022 | 58 | 0.720 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 74 | 0.670 |
Why?
|
| Infection Control | 1 | 2021 | 158 | 0.650 |
Why?
|
| Electrocardiography | 4 | 2023 | 989 | 0.650 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 80 | 0.620 |
Why?
|
| Humans | 70 | 2025 | 132348 | 0.590 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 304 | 0.560 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 903 | 0.540 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 56 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 305 | 0.470 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 697 | 0.430 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 471 | 0.430 |
Why?
|
| Hypokalemia | 1 | 2014 | 39 | 0.420 |
Why?
|
| Adult | 22 | 2025 | 31619 | 0.420 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 483 | 0.420 |
Why?
|
| Pain Measurement | 5 | 2024 | 351 | 0.410 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 25 | 0.410 |
Why?
|
| Patient Discharge | 5 | 2025 | 513 | 0.410 |
Why?
|
| Biomarkers | 9 | 2025 | 3391 | 0.410 |
Why?
|
| Predictive Value of Tests | 6 | 2025 | 2303 | 0.390 |
Why?
|
| Fever | 1 | 2015 | 312 | 0.390 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 186 | 0.380 |
Why?
|
| Insulin | 4 | 2023 | 1211 | 0.370 |
Why?
|
| Ischemia | 1 | 2015 | 373 | 0.370 |
Why?
|
| Acute Disease | 4 | 2025 | 1176 | 0.370 |
Why?
|
| Albuterol | 2 | 2023 | 49 | 0.350 |
Why?
|
| Pain Management | 5 | 2024 | 199 | 0.340 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2023 | 98 | 0.340 |
Why?
|
| Middle Aged | 19 | 2025 | 28891 | 0.340 |
Why?
|
| Acetaminophen | 2 | 2024 | 97 | 0.330 |
Why?
|
| Vitamin D | 2 | 2021 | 180 | 0.320 |
Why?
|
| Ketamine | 2 | 2023 | 225 | 0.300 |
Why?
|
| Sufentanil | 2 | 2019 | 4 | 0.300 |
Why?
|
| Mental Disorders | 3 | 2025 | 893 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 288 | 0.300 |
Why?
|
| Acute Pain | 2 | 2019 | 17 | 0.290 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 803 | 0.290 |
Why?
|
| Female | 24 | 2025 | 70795 | 0.280 |
Why?
|
| Pilot Projects | 3 | 2022 | 1454 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2024 | 6540 | 0.280 |
Why?
|
| Male | 22 | 2025 | 65061 | 0.270 |
Why?
|
| Cystatin C | 2 | 2025 | 65 | 0.270 |
Why?
|
| Analgesia | 2 | 2024 | 43 | 0.240 |
Why?
|
| Prognosis | 9 | 2025 | 5010 | 0.240 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2025 | 31 | 0.230 |
Why?
|
| Aftercare | 2 | 2023 | 155 | 0.230 |
Why?
|
| Nasal Sprays | 1 | 2024 | 8 | 0.220 |
Why?
|
| Undocumented Immigrants | 1 | 2024 | 13 | 0.220 |
Why?
|
| Dyspnea | 2 | 2025 | 159 | 0.220 |
Why?
|
| Vitamins | 2 | 2021 | 113 | 0.220 |
Why?
|
| Hospitals | 3 | 2023 | 436 | 0.220 |
Why?
|
| Ketorolac | 1 | 2024 | 11 | 0.220 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 32 | 0.220 |
Why?
|
| Triage | 1 | 2025 | 148 | 0.210 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2025 | 82 | 0.210 |
Why?
|
| Renal Dialysis | 2 | 2022 | 889 | 0.210 |
Why?
|
| Dietary Supplements | 3 | 2022 | 482 | 0.210 |
Why?
|
| Microfluidics | 1 | 2024 | 28 | 0.210 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2023 | 5 | 0.210 |
Why?
|
| Hematology | 1 | 2024 | 43 | 0.210 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 1061 | 0.210 |
Why?
|
| Ethics Committees, Research | 1 | 2023 | 32 | 0.200 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2024 | 104 | 0.200 |
Why?
|
| Cholesterol, HDL | 1 | 2024 | 395 | 0.200 |
Why?
|
| Trace Elements | 1 | 2022 | 26 | 0.190 |
Why?
|
| Monocytes | 1 | 2024 | 345 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 311 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2024 | 365 | 0.190 |
Why?
|
| Peritoneum | 1 | 2002 | 39 | 0.190 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 85 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2025 | 339 | 0.190 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 108 | 0.190 |
Why?
|
| Milrinone | 1 | 2022 | 30 | 0.190 |
Why?
|
| Aggression | 1 | 2024 | 230 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2025 | 799 | 0.180 |
Why?
|
| Neutrophils | 1 | 2024 | 359 | 0.180 |
Why?
|
| Self Report | 1 | 2025 | 552 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 7111 | 0.180 |
Why?
|
| Status Epilepticus | 1 | 2023 | 156 | 0.180 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 73 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1247 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2021 | 32 | 0.170 |
Why?
|
| Airway Extubation | 1 | 2021 | 70 | 0.170 |
Why?
|
| Laryngoscopes | 1 | 2022 | 71 | 0.170 |
Why?
|
| Calcitonin | 1 | 2020 | 32 | 0.170 |
Why?
|
| Myocarditis | 1 | 2021 | 130 | 0.170 |
Why?
|
| Medication Systems, Hospital | 1 | 2019 | 45 | 0.160 |
Why?
|
| Influenza, Human | 2 | 2024 | 700 | 0.160 |
Why?
|
| Protein Precursors | 1 | 2020 | 156 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 482 | 0.160 |
Why?
|
| Hospitalization | 3 | 2023 | 1894 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 274 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 498 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2021 | 277 | 0.150 |
Why?
|
| Sodium Bicarbonate | 1 | 2019 | 56 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 831 | 0.150 |
Why?
|
| Cesarean Section | 1 | 2002 | 407 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 911 | 0.150 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 288 | 0.150 |
Why?
|
| Diuretics | 1 | 2019 | 156 | 0.140 |
Why?
|
| Codeine | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hydrocodone | 1 | 2018 | 37 | 0.140 |
Why?
|
| Algorithms | 1 | 2025 | 1722 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1076 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 897 | 0.140 |
Why?
|
| Aged | 10 | 2025 | 21381 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17364 | 0.140 |
Why?
|
| Pandemics | 5 | 2023 | 1188 | 0.140 |
Why?
|
| Influenza B virus | 1 | 2018 | 100 | 0.140 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 6 | 0.130 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 13 | 0.130 |
Why?
|
| Professional Practice Gaps | 1 | 2017 | 15 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2017 | 30 | 0.130 |
Why?
|
| United States | 6 | 2025 | 11628 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2018 | 152 | 0.130 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 51 | 0.130 |
Why?
|
| Incidence | 3 | 2022 | 3362 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 179 | 0.130 |
Why?
|
| Ketorolac Tromethamine | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cardiology | 1 | 2021 | 497 | 0.120 |
Why?
|
| Registries | 1 | 2023 | 1585 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2020 | 488 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 390 | 0.120 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 140 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 728 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 212 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 544 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 93 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 193 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 667 | 0.120 |
Why?
|
| Prevalence | 2 | 2024 | 2665 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 742 | 0.110 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2018 | 233 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2024 | 13017 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2016 | 165 | 0.110 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2015 | 43 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 104 | 0.110 |
Why?
|
| Leg | 1 | 2015 | 134 | 0.110 |
Why?
|
| Potassium Chloride | 1 | 2014 | 48 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1083 | 0.110 |
Why?
|
| Checklist | 2 | 2025 | 96 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 407 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2024 | 249 | 0.100 |
Why?
|
| Medicare | 1 | 2017 | 448 | 0.100 |
Why?
|
| Stroke | 1 | 2021 | 1068 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 818 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 3198 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 326 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1163 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 680 | 0.090 |
Why?
|
| Thymidylate Synthase | 2 | 2004 | 21 | 0.090 |
Why?
|
| Risk Factors | 4 | 2025 | 10911 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1648 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3745 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2931 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2015 | 1229 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1305 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1153 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3710 | 0.080 |
Why?
|
| Administration, Sublingual | 2 | 2019 | 13 | 0.080 |
Why?
|
| Myocardium | 1 | 2014 | 908 | 0.070 |
Why?
|
| Child | 4 | 2025 | 25827 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2145 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2025 | 66 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2025 | 115 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 135 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2025 | 319 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 25 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2024 | 69 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 159 | 0.050 |
Why?
|
| ROC Curve | 1 | 2025 | 598 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 78 | 0.050 |
Why?
|
| Violence | 1 | 2024 | 126 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 216 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 252 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 255 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 107 | 0.050 |
Why?
|
| Glycopeptides | 1 | 2022 | 28 | 0.050 |
Why?
|
| Leukocytes | 1 | 2024 | 210 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 34 | 0.050 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2002 | 17 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 77 | 0.050 |
Why?
|
| Analgesia, Obstetrical | 1 | 2002 | 9 | 0.050 |
Why?
|
| Dobutamine | 1 | 2022 | 56 | 0.050 |
Why?
|
| Morphine | 1 | 2002 | 85 | 0.050 |
Why?
|
| Protective Factors | 1 | 2022 | 90 | 0.050 |
Why?
|
| Zinc | 1 | 2022 | 140 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 126 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2002 | 161 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 400 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 135 | 0.040 |
Why?
|
| Health Promotion | 1 | 2024 | 404 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2023 | 389 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 534 | 0.040 |
Why?
|
| Survival Rate | 1 | 2025 | 2187 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2020 | 87 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 268 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 478 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 312 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1017 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 15 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2025 | 802 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 246 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 895 | 0.030 |
Why?
|
| Tablets | 1 | 2017 | 35 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2018 | 88 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 279 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 210 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2228 | 0.030 |
Why?
|
| Length of Stay | 1 | 2002 | 1378 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 492 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 590 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1331 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5150 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 34995 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 672 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 826 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2018 | 377 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1672 | 0.030 |
Why?
|
| Enzyme Stability | 2 | 2004 | 59 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 922 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2004 | 309 | 0.020 |
Why?
|
| Ligands | 2 | 2004 | 495 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9945 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3629 | 0.020 |
Why?
|
| Pregnancy | 1 | 2002 | 7567 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3087 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6248 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6456 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20553 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 97 | 0.010 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2004 | 23 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 269 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 381 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2004 | 142 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 143 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 764 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 825 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2673 | 0.010 |
Why?
|
| Floxuridine | 1 | 1999 | 8 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3780 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2730 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 637 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1047 | 0.010 |
Why?
|
| Protein Binding | 1 | 1999 | 1735 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 2904 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1999 | 2687 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 4725 | 0.010 |
Why?
|